KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Shares Issued (2016 - 2025)

Rigel Pharmaceuticals has reported Shares Issued over the past 16 years, most recently at $2.9 million for Q4 2025.

  • Quarterly results put Shares Issued at $2.9 million for Q4 2025, up 99.86% from a year ago — trailing twelve months through Dec 2025 was $8.1 million (up 312.47% YoY), and the annual figure for FY2025 was $8.1 million, up 312.47%.
  • Shares Issued for Q4 2025 was $2.9 million at Rigel Pharmaceuticals, down from $4.3 million in the prior quarter.
  • Over the last five years, Shares Issued for RIGL hit a ceiling of $4.3 million in Q3 2025 and a floor of $1000.0 in Q1 2023.
  • Median Shares Issued over the past 5 years was $553000.0 (2023), compared with a mean of $948052.6.
  • Biggest five-year swings in Shares Issued: tumbled 99.89% in 2023 and later soared 8800.0% in 2024.
  • Rigel Pharmaceuticals' Shares Issued stood at $1.1 million in 2021, then crashed by 46.08% to $585000.0 in 2022, then fell by 16.92% to $486000.0 in 2023, then soared by 201.44% to $1.5 million in 2024, then skyrocketed by 99.86% to $2.9 million in 2025.
  • The last three reported values for Shares Issued were $2.9 million (Q4 2025), $4.3 million (Q3 2025), and $418000.0 (Q2 2025) per Business Quant data.